
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
A study performed by St. Louis University found that approximately 7.8 million Americans are living with hyperhydrosis, a condition that often results in anxiety and depression.